Investigation Report on China Valsartan Market, 2009-2018
Reportstack, provider of premium market research reports announces the addition of Investigation Report on China Valsartan Market, 2009-2018 market report to its offering
Valsartan (Angiotan or Diovan) is an angiotensin II receptor antagonist (more commonly called an ARB, or angiotensin receptor blocker), with particularly high affinity for the type I (AT1) angiotensin receptor. In December 1996, Valsartan was approved by FDA. In the US, UK and Australia, valsartan is marketed by Novartis under the trade name Diovan. In 1998, Valsartan...
View full press release